Compare NWGL & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWGL | TOVX |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 10.1M |
| IPO Year | 2022 | 2012 |
| Metric | NWGL | TOVX |
|---|---|---|
| Price | $1.61 | $0.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | ★ 1.6M | 427.7K |
| Earning Date | 05-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.16 |
| 52 Week High | $1.82 | $0.86 |
| Indicator | NWGL | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 74.59 | 42.01 |
| Support Level | $1.11 | $0.22 |
| Resistance Level | N/A | $0.26 |
| Average True Range (ATR) | 0.27 | 0.01 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 79.67 | 20.90 |
CL Workshop Group Ltd, formerly Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.